Orca-T for Graft-Versus-Host Disease: Mehrdad Abedi, MD

Video

The professor of medicine at the UC Davis Comprehensive Cancer Center discussed Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.

This content originally appeared on our sister site, Targeted Oncology.

Targeted Oncology spoke with Mehrdad Abedi, MD, a professor of cancer, hematology/oncology, and internal medicine in the Department of Internal Medicine, Division of Hematology and Oncology at the UC Davis Comprehensive Cancer Center, about Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease (GVHD).

The therapy was developed by Orca Bio, who approached UC Davis a few years ago to start collaborative research with the Good Manufacturing Practice facility and produce these products. Each graft of the Orca-T product has stem cells and immune cells in it. The stem cells are needed to maintain the graft and allow the product to stay in the patient for a long time, according to Abedi. The immune cells cause graft-vs-leukemia effects, which is what they want.

Abedi says it is clear that there is a population of T cells called T-regulatory cells that can prevent GVHD as seen in work from multiple investigators. There are other populations, such as the naïve T cells or conventional T cells, that can cause GVHD. A smaller number of those cell may be helpful; they can cause graft-vs-leukemia, but not GVHD.

The graft is designed so that the investigators can give stem cells, but they remove a lot of conventional T cells that can cause GVHD. The graft provides a small amount of conventional T cells that can cause graft-vs-leukemia effects, as well as the regulatory T cells that can prevent GVHD, Abedi explains.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.